Early diagnosis and treatment may reduce MS relapses

By Charles Smith, MD, Scripps Health

Multiple sclerosis is a chronic autoimmune disease that disrupts nerve impulses in the central nervous system (brain, optic nerves and spinal cord) by attacking the protective coverings around nerve fibers known as myelin, and often damaging the nerve fibers (axons) themselves. Consequently, it can cause a diverse range of symptoms including numbness, weakness, spasticity, gait disturbances, bladder problems, cognitive and memory problems, speech disorders, vision problems and others.

Often referred to simply as MS, multiple sclerosis is believed to affect more than 2.5 million people worldwide, including approximately 400,000 people in the U.S.  Another 200 are newly diagnosed in the U.S. every week. It is three times more common in women than men, and is most often diagnosed between the ages of 20 and 50, although rarely has it been shown to affect infants and elderly people.

The cause of MS is unknown, but genetics and environmental factors may influence its onset. Though it is not directly inherited from a parent, the risk of developing MS is greater in people who have a close relative, such as a parent or sibling, with the disease. It is more common among Caucasians than other ethnic groups. Because women are affected more often than men, researchers are studying whether hormones may play a role. Worldwide, MS is more common in areas farther from the equator, which has led researchers to conclude that exposure to sunlight and low vitamin D levels influence the development of MS. Another confirmed environmental factor is smoking.

Most researchers believe the disease is triggered by exposure to a virus — Epstein Barr virus is the current leading candidate — but proof is not yet available.

MS is often not diagnosed right away because so many of its symptoms may be caused by other conditions. In most cases, a neurologist will diagnose the disease after a thorough physical examination and a brain MRI, which will reveal abnormalities on the brain. Lumbar puncture (spinal tap) is often included in the work up to confirm that the diagnosis is indeed MS.

Once treatment is initiated, a brain MRI is usually done annually to ensure treatment is maximally effective.

Because MS is most frequently an episodic disease, patients experience relapses and remissions, and symptoms can vary from one episode to the next. Major symptoms may disappear completely between relapses. In severe cases, symptoms such as speech or vision problems or paralysis may become permanent.

Treatment focuses on relieving symptoms and reducing the frequency of relapses and preventing disability.  Historically, MS patients who receive no treatment have had an average of about one relapse (exacerbation) per year.  New treatments discovered over the past two decades have shown significant progress in reducing the relapse rate and disability progression.  Moreover, the earlier treatment is started, the more effective it may be. The first drugs approved for MS were immunomodulators. These so-called “platform drugs” for MS were approved in the 1990s and include interferons, such as Betaseron, Avonex and Rebif. Copaxone, another platform treatment, is in a separate class.

Immunomodulators stop the body from damaging its own nerve cells; in the initial clinical trials, these drugs reduced the relapse rate by about 30 percent. However, the patients in these trials had been diagnosed five or six years before beginning treatment and already had substantial myelin damage and brain abnormalities. When the researchers began earlier treatment that included patients who had just a single episode and minimal abnormalities on the brain MRI, the relapse rate dropped to about 50 percent with these treatments.

Not all MS patients respond to the platform drugs, and some may experience unpleasant side effects such as flu-like symptoms with the interferons. In some cases, these side effects are intolerable, and treatment must be discontinued. A growing list of new approved medications is now available for MS and may have better results, but some of these also have potentially serious side effects that must be carefully considered before beginning treatment.

Because early diagnosis and treatment can significantly help reduce the relapse rate and slow the progression of the disease, patients with potential MS symptoms should be examined by a neurologist and have a brain MRI as soon as possible.

Charles Smith, M.D., is a neurologist with Scripps Clinic. Join Dr. Smith for a free spring lecture series on multiple sclerosis on June 13. For more information or to register, please call 1-800-SCRIPPS.


Related posts:

  1. Multiple Sclerosis symptoms require individualized management
  2. To Your Health: The many faces of a cancer diagnosis
  3. Free screening offers early detection of Type 1 diabetes
  4. Living with Dementia: Help is available
  5. UCSD report: Marijuana found to have value in pain treatment

Short URL: http://www.delmartimes.net/?p=51804

Posted by Lorine Wright on Jun 8, 2013. Filed under Letters, Opinion. You can follow any responses to this entry through the RSS 2.0. You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply

Archives

Facebook

Bottom Buttons 1

Bottom Buttons 2

Bottom Buttons 3

Bottom Buttons 4

Bottom Buttons 5

Bottom Buttons 6

LA JOLLA NEWS

RANCHO SANTA FE NEWS

RANCHO SANTA FE NEWS

RSS RANCHO SANTA FE NEWS

  • Next step in Rancho Santa Fe Garden Club sale likely to be mid-October
    The Rancho Santa Fe Garden Club board won’t likely make a decision on the sale of its clubhouse until mid-October, according to co-president Fred Wasserman. The 1.04-acre property, home to the 7,974-square-foot clubhouse, has been listed with Colliers International and the realtors are handling all offers submitted. Nobody on the board is discussing the offe […]
  • Rancho Santa Fe water district director resigns after qualifying for ballot
    An announcement by John Ingalls, a 12-year veteran of the Santa Fe Irrigation District board, that he would immediately step down from his seat and not seek a fourth term, means that none of the three open seats on the panel will be contested at the voting booth this November. Ingalls, a Rancho Santa Fe resident who had filed his papers to run for a fourth t […]
  • Rancho Santa Fe resident among seven new trustees joining UC San Diego Foundation Board
    Proactive stewards, higher education advocates and expert financial strategists, UC San Diego Foundation trustees play an important role in cultivating community partnerships and garnering resources to support UC San Diego research, teaching and public service initiatives. Trustees govern the Foundation, including managing net assets totaling $717 million, i […]